World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
57560
World Ranking
8121
National Ranking
4211

Overview

Evan A. Stein is affiliated with Medpace in the United States and has contributed to the fields of Medicine and Economics, Econometrics and Finance. Their research primarily focuses on Lipoproteins and Cardiovascular Health, with additional work in Pharmaceutical Economics and Policy, Cancer related to Lipids and Metabolism, Health Systems and Economic Evaluations, and Diabetes and Cardiovascular Risks.

Their work spans multiple subfields including Surgery, Economics and Econometrics, Cancer Research, Endocrinology, Diabetes and Metabolism, and Genetics. This multidisciplinary approach is reflected in publications across several high-profile journals, with frequent appearances in:

  • Atherosclerosis
  • Journal of the American College of Cardiology
  • JAMA Cardiology
  • The Lancet Diabetes & Endocrinology
  • Journal of clinical lipidology

Some of their most recent papers include:

  • Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis (2021, JAMA Cardiology)
  • Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020, Journal of the American College of Cardiology)
  • Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial (2023, European Heart Journal)
  • Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease (2024, JAMA Cardiology)
  • Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study (2022, Schizophrenia Bulletin)

Frequent co-authors in their work include:

  • Frederick J. Raal
  • David Kallend
  • Dirk Blom
  • Traci Turner
  • Meral Kayıkçıoğlu

Best Publications

  • Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS

    John R. Downs;Michael Clearfield;Stephen Weis;Edwin Whitney

  • Estrogen plus progestin and the risk of coronary heart disease

    JoAnn A E Manson;Judith Hsia;Karen C. Johnson;Jacques E. Rossouw

  • Design of the Women's Health Initiative clinical trial and observational study

    G. Anderson;S. Cummings;L. S. Freedman;C. Furberg

  • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)

    Peter H Jones;Michael H Davidson;Evan A Stein;Harold E Bays

  • Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

    John J.P. Kastelein;Fatima Akdim;Erik S.G. Stroes;Aeilko H. Zwinderman

  • Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

    Sylvia Wassertheil-Smoller;Susan Hendrix;Marian Limacher;Gerardo Heiss

  • Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S. Stroes;Paul D. Thompson;Alberto Corsini;Georgirene D. Vladutiu

  • Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

    Evan A. Stein;Scott Mellis;George D. Yancopoulos;Neil Stahl

  • A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

    Dirk J. Blom;Tomas Hala;Michael Bolognese;Michael J. Lillestol

  • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial

    Frederick J Raal;Evan A Stein;Robert Dufour;Traci Turner

  • Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

    Antonio M. Gotto;Edwin Whitney;Evan A. Stein;Deborah R. Shapiro

  • Inhibition of PCSK9 With Evolocumab in Homozygous Familial Hypercholesterolaemia (TESLA Part B): A Randomised, Double-Blind, Placebo-Controlled Trial

    Frederick J Raal;Narimon Honarpour;Dirk J Blom;G Kees Hovingh

  • Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

    Evan A Stein;Dan Gipe;Jean Bergeron;Daniel Gaudet

  • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

    James M. McKenney;Michael J. Koren;Dean J. Kereiakes;Corinne Hanotin

  • Implementation of the Women's Health Initiative study design.

    Garnet L. Anderson;Joann Manson;Robert Wallace;Bernedine Lund

  • Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial

    Frederick Raal;Rob Scott;Ransi Somaratne;Ian Bridges

  • Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia

    Mariann Grossman;Steven E. Raper;Steven E. Raper;Karen Kozarsky;Karen Kozarsky;Evan A. Stein

  • A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

    Grossman M;Rader Dj;Muller Dw;Kolansky Dm

  • Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

    Eli M. Roth;James M. McKenney;Corinne Hanotin;Gaelle Asset

  • Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    M.S. Sabatine;R.P. Giugliano;S.D. Wiviott

Frequent Co-Authors

Frederick J. Raal
Frederick J. Raal University of the Witwatersrand
Harold E. Bays
Harold E. Bays Louisville Metabolic and Atherosclerosis Research Center
Christie M. Ballantyne
Christie M. Ballantyne Baylor College of Medicine
Michael H. Davidson
Michael H. Davidson University of Chicago
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Daniel Gaudet
Daniel Gaudet University of Montreal
Robert H. Knopp
Robert H. Knopp University of Washington
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Antonio M. Gotto
Antonio M. Gotto Cornell University
Robert P. Giugliano
Robert P. Giugliano Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine as a field opens up numerous pathways beyond traditional MD programs. Many allied health professionals are enhancing their careers with flexible, online education. For example, adn to np bridge programs allow registered nurses with an associate’s degree to advance smoothly into nurse practitioner roles—without stepping away from their current job.

Another growing area is nutrition. By completing online nutrition degrees, students can pursue roles in dietetics, food science, or wellness coaching, conveniently from home at their own pace.

If your interest lies in healthcare leadership, top cahme-accredited mha programs offer a direct route to administrative positions such as hospital manager or healthcare consultant.

For RNs looking to expand their credentials, consider enrolling in rn to bsn with no clinicals programs, which provide academic advancement without the need for additional clinical hours.

These online degree pathways can provide valuable flexibility, making it easier for aspiring healthcare professionals to upskill and advance in their careers.

Best Scientists Citing Evan A. Stein

Trending Scientists

Recently Published Articles